Literature DB >> 9126337

The cloning and characterization of a murine secretory leukocyte protease inhibitor cDNA.

R J Zitnik1, J Zhang, M A Kashem, T Kohno, D E Lyons, C D Wright, E Rosen, I Goldberg, A C Hayday.   

Abstract

Human secretory leukocyte protease inhibitor (hSLPI) is produced by epithelial cells at mucosal surfaces, where it regulates both the neutrophil-mediated inflammation that characterizes inflammatory diseases, and pathogens themselves via both antiprotease and "defensin-like" activities. Additionally, hSLPI may regulate other processes such as cutaneous desquamation and placental invasiveness. To better understand the primary physiologic roles of SLPI, it will be important to establish a genetically tractable animal model, the most attractive candidate being the mouse. In this report, the cloning and characterization of murine (m) SLPI is described. mSLPI is encoded by a single copy gene, and appears structurally highly similar to hSLPI. At the same time, significant differences between mSLPI and hSLPI are presented, notably a difference in expression pattern, and a structural difference in the protease binding site that correlates with a difference in the spectrum of protease inhibiton. Such species-specific evolution of this protease inhibitor is notable given that species-specific structure-function differences have previously been reported for the alpha-1 antitrypsin family.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9126337     DOI: 10.1006/bbrc.1997.6358

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  8 in total

1.  Characterization of the ovine ortholog of secretory leukoprotease inhibitor.

Authors:  Thomas I Brown; Rohit Mistry; Robert Gray; Margaret Imrie; David D Collie; Jean-Michel Sallenave
Journal:  Mamm Genome       Date:  2005-09-14       Impact factor: 2.957

2.  Lipopolysaccharide-related stimuli induce expression of the secretory leukocyte protease inhibitor, a macrophage-derived lipopolysaccharide inhibitor.

Authors:  F Jin; C F Nathan; D Radzioch; A Ding
Journal:  Infect Immun       Date:  1998-06       Impact factor: 3.441

3.  The porcine chloride channel calcium-activated family member pCLCA4a mirrors lung expression of the human hCLCA4.

Authors:  Stephanie Plog; Tanja Grötzsch; Nikolai Klymiuk; Ursula Kobalz; Achim D Gruber; Lars Mundhenk
Journal:  J Histochem Cytochem       Date:  2012-01       Impact factor: 2.479

4.  Secretory leukocyte protease inhibitor promotes the tumorigenic and metastatic potential of cancer cells.

Authors:  Nick Devoogdt; Gholamreza Hassanzadeh Ghassabeh; Jing Zhang; Lea Brys; Patrick De Baetselier; Hilde Revets
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-05       Impact factor: 11.205

5.  Inhibition of SLPI ameliorates disease activity in experimental autoimmune encephalomyelitis.

Authors:  André Michael Müller; Esther Jun; Hana Conlon; Saud Ahmed Sadiq
Journal:  BMC Neurosci       Date:  2012-03-21       Impact factor: 3.288

6.  Secretory leukocyte protease inhibitor suppresses the inflammation and joint damage of bacterial cell wall-induced arthritis.

Authors:  X y Song; L Zeng; W Jin; J Thompson; D E Mizel; K Lei; R C Billinghurst; A R Poole; S M Wahl
Journal:  J Exp Med       Date:  1999-08-16       Impact factor: 14.307

7.  Interferon gamma induction of pulmonary emphysema in the adult murine lung.

Authors:  Z Wang; T Zheng; Z Zhu; R J Homer; R J Riese; H A Chapman; S D Shapiro; J A Elias
Journal:  J Exp Med       Date:  2000-12-04       Impact factor: 14.307

8.  Novel role for SLPI in MOG-induced EAE revealed by spinal cord expression analysis.

Authors:  Andre M Mueller; Xiomara Pedré; Thomas Stempfl; Ingo Kleiter; Sebastien Couillard-Despres; Ludwig Aigner; Gerhard Giegerich; Andreas Steinbrecher
Journal:  J Neuroinflammation       Date:  2008-05-26       Impact factor: 8.322

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.